Nevada Diabetes Drug Pricing Law Targeted By PhRMA/BIO Lawsuit
Law requires manufacturers to report production, marketing costs and pricing details that would be publicly released by state health department. Trade groups' lawsuit argues requirements are unconstitutional.
You may also be interested in...
Regulations allow manufacturers to request that drug production and marketing costs and price contracting information provided to the state be kept confidential.
Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.
Rx manufacturers must notify state purchasers, health care plans and PBMs of price hikes on drugs with a wholesale acquisition cost greater than $40; follows at least five other state laws, including those of Vermont and Nevada.